Clinical Research Directory
Browse clinical research sites, groups, and studies.
Intervention of Ovarian Cancer With Antigen-specific Engineered Immune Effectors
Sponsor: Shenzhen Geno-Immune Medical Institute
Summary
This is a single-arm, open-label, phase I/II trial to evaluate the safety and efficacy of ovarian cancer-specific, engineered immune effectors (OC-EIEs) in women.
Official title: Interventional Treatment of Ovarian Cancer With Cancer Antigen-specific Engineered Immune Effector T Lymphocytes (OC-EIEs)
Key Details
Gender
FEMALE
Age Range
10 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-12-01
Completion Date
2028-12-31
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
OC-EIEs
2 to 4 infusions, once a week, 0.1\~4x10\^6 CTLs/kg; injection via IV, abdominal cavity or intrastumoral.
Locations (1)
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China